- 1-800-ORENCIA
- Full Prescribing Information
- Indications
- Patient Site
- BMS Resources
This site is intended for US-based Health Care Professionals only.
In moderate to severe RA
ORENCIA has an established safety
and efficacy profile
Evaluated in studies that included patients
with comorbidities13-16
Advancing age
Diabetes
Cardiovascular disease
High blood pressure
High cholesterol
High BMI
Patients had at least 1 comorbid
condition in 4 studies:
Choose ORENCIA when considering
the whole patient
There were no subgroup analyses conducted
evaluating the safety and
efficacy of ORENCIA
in patients with comorbidities.
ORENCIA is in a class of its own
Unique MOA: t-cell immunomodulation18-33
ORENCIA works differently than other
medications by modulating the T-cell early in
the cascade that triggers both key pathways in
the RA immune response.
This relationship between these biological
response markers to the mechanisms by
which
ORENCIA exerts it’s effects in RA is unknown.
AG, antigen; BMI, body mass index; CD, cluster of differentiation; IL-6, interleukin-6; IV, intravaneous; JAK-STAT, Janus kinase/signal transducer and activator of transcription; MHC, major histocompatibility complex; MOA, mechanism of action; MTX, methotrexate; RA, rheumatoid arthritis; TCR, T-cell receptor; TNFi-IR inadequate response to a tumor necrosis factor inhibitor.
*According to the Food and Drug Administration (FDA) Biosimilar Product Information page. Valid as of February 2024.
References: 1. Data on File. REF-01232-427. Princeton, NJ: Bristol Myers Squibb. 2. Schiff M, Weinblatt ME, Valente R, et al. Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial. Ann Rheum Dis. 2014;73(1):86-94. doi:10.1136/annrheumdis-2013-203843. 3. Emery P, Burmester GR, Bykerk VP, et al. Evaluating drug-free remission with abatacept in early rheumatoid arthritis: results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24 months, with a 12-month, double-blind treatment period. Ann Rheum Dis. 2015;74(1):19-26. doi:10.1136/annrheumdis-2014-206106. 4. Schiff M, Keiserman M, Codding C, et al. Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Ann Rheum Dis. 2008;67(8):1096-1103. doi:10.1136/ard.2007.080002. 5. Kaine J, Gladstein G, Strusberg I, et al. Evaluation of abatacept administered subcutaneously in adults with active rheumatoid arthritis: impact of withdrawal and reintroduction on immunogenicity, efficacy and safety (phase IIIb ALLOW study). Ann Rheum Dis. 2012;71(1):38-44. doi:10.1136/annrheumdis-2011-200344. 6. Nash P, Nayiager S, Genovese MC, et al. Immunogenicity, safety, and efficacy of abatacept administered subcutaneously with or without background methotrexate in patients with rheumatoid arthritis: results from a phase III, international, multicenter, parallel-arm, open-label study. Arthritis Care Res (Hoboken). 2013;65(5):718-728. doi:10.1002/acr.21876. 7. Keystone EC, Kremer JM, Russell A, et al. Abatacept in subjects who switch from intravenous to subcutaneous therapy: results from the phase IIIb ATTUNE study. Ann Rheum Dis. 2012;71(6):857-861. doi:10.1136/annrheumdis-2011-200355. 8. Weinblatt M, Combe B, Covucci A, Aranda R, Becker JC, Keystone E. Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: A one-year randomized, placebo-controlled study. Arthritis Rheum. 2006;54(9):2807-2816. doi:10.1002/art.22070. 9. Weinblatt ME, Schiff M, Valente R, et al. Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: findings of a phase IIIb, multinational, prospective, randomized study. Arthritis Rheum. 2013;65(1):28-38. doi:10.1002/art.37711. 10. Westhovens R, Robles M, Ximenes AC, et al. Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors. Ann Rheum Dis. 2009;68(12):1870-1877. doi:10.1136/ard.2008.101121. 11. Genovese MC, Covarrubias A, Leon G, et al. Subcutaneous abatacept versus intravenous abatacept: a phase IIIb noninferiority study in patients with an inadequate response to methotrexate. Arthritis Rheum. 2011;63(10):2854-2864. doi:10.1002/art.30463. 12. Moreland LW, Alten R, Van den Bosch F, et al. Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion. Arthritis Rheum. 2002;46(6):1470-1479. doi:10.1002/art.10294. 13. Data on File. REF-01227-427. Princeton, NJ: Bristol Myers Squibb. 14. Data on File. REF-01226-427. Princeton, NJ: Bristol Myers Squibb. 15. Data on File. REF-01228-427. Princeton, NJ: Bristol Myers Squibb. 16. Mariette X, Alten R, Nüßlein HG, et al. The effect of body mass index on clinical response to abatacept as a first-line biologic for rheumatoid arthritis: 6-month results from the 2-year, observational, prospective ACTION study. Joint Bone Spine. 2017;84(5):571-576. doi:10.1016/j.jbspin.2016.10.011. 17. Genovese MC, Becker JC, Schiff M, et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition [published correction appears in N Engl J Med. 2005 Nov 24;353(21):2311]. N Engl J Med. 2005;353(11):1114-1123. doi:10.1056/NEJMoa050524. 18. ORENCIA® [package insert]. Princeton, NJ: Bristol Myers Squibb. 19. Enbrel® [package insert]. Thousand Oaks, CA: Amgen Inc. 20. RINVOQ® [package insert]. North Chicago, IL: AbbVie Inc. 21. CIMZIA® [package insert]. Smyrna, GA: UCB, Inc. 22. HUMIRA® Injection [package insert]. North Chicago, IL: AbbVie Inc. 23. KEVZARA® [package insert]. Bridgewater, NJ: Sanofi/Regeneron Pharmaceuticals, Inc. 24. Olumiant® [package insert]. Indianapolis, IN: Eli Lilly and Company. 25. REMICADE® [package insert]. Horsham, PA: Janssen Biotech, Inc. 26. SIMPONI ARIA® (golimumab) [package insert]. Horsham, PA: Janssen Biotech, Inc. 27. XELJANZ® [package insert]. New York, NY: Pfizer Inc. 28. ACTEMRA® [package insert]. South San Francisco, CA: Genentech, Inc. 29. Willemze A, Trouw LA, Toes RE, Huizinga TW. The influence of ACPA status and characteristics on the course of RA. Nat Rev Rheumatol. 2012;8(3):144-152. doi:10.1038/nrrheum.2011.204. 30. Malmström V, Trollmo C, Klareskog L. Modulating co-stimulation: a rational strategy in the treatment of rheumatoid arthritis? Arthritis Res Ther. 2005;7(Suppl2):S15-S20. doi:10.1186/ar1505. 31. Klareskog L, Rönnelid J, Lundberg K, Padyukov L, Alfredsson L. Immunity to citrullinated proteins in rheumatoid arthritis. Annu Rev Immunol. 2008;26:651-675. doi:10.1146/annurev.immunol.26.021607.090244. 32. Choy E. Understanding the dynamics: pathways involved in the pathogenesis of rheumatoid arthritis. Rheumatology (Oxford). 2012;51(suppl 5):v3-v11. doi:10.1093/rheumatology/kes113. 33. Sokolove J, Zhao X, Chandra PE, Robinson WH. Immune complexes containing citrullinated fibrinogen costimulate macrophages via Toll-like receptor 4 and Fcγ receptor. Arthritis Rheum. 2011;63(1):53-62. doi:10.1002/art.30081. 34. Heinrich PC, Behrmann I, Müller-Newen G, Schaper F, Graeve L. Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway. Biochem J. 1998;334 (Pt2):297-314. doi:10.1042/bj3340297.